K M Anderson Selected Research

MK-886

1/2005	Disparate forms of MK 886-induced programmed death in BCL-2 (+) blood and BCL-2 (-) solid cancer cells and a putative "nuclear" Ca2+ channel: "soil" trumps "seed"?
1/2005	Reactive oxygen species and redox-induced programmed cell death due to MK 886: cells ("soil") "trump" agent ("seed").
9/2004	Acute changes in U937 nuclear Ca2+ preceding type 1 "apoptotic" programmed cell death due to MK 886.
11/2003	An interaction between type 1 and type 2 programmed cell death and clonogenic survival.
4/2002	Increased cytosol Ca(2+) and type 1 programmed cell death in Bcl-2-positive U937 but not in Bcl-2-negative PC-3 and Panc-1 cells induced by the 5-lipoxygenase inhibitor MK 886.
5/2001	The mode of cell death in H-358 lung cancer cells cultured with inhibitors of 5-lipoxygenase or the free radical spin trap, NTBN.
7/2000	A genomic response of H-358 bronchiolar carcinoma cells to MK 886, an inhibitor of 5-lipoxygenase, assessed with a cDNA array.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

K M Anderson Research Topics

Disease

10	Neoplasms (Cancer) 01/2014 - 07/2000
4	Pancreatic Neoplasms (Pancreatic Cancer) 09/2004 - 06/2001
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 11/2006 - 01/2005
2	Hypoxia (Hypoxemia) 02/2011 - 11/2009
2	Hypertension (High Blood Pressure) 07/2007 - 05/2007
2	Stroke (Strokes) 05/2005 - 10/2001
2	Myeloid Leukemia (Leukemia, Myelocytic) 01/2005 - 04/2002
1	Prostatic Neoplasms (Prostate Cancer) 01/2014
1	Latent Tuberculosis 09/2011
1	Necrosis 11/2009
1	Insulin Resistance 07/2007
1	Type 2 Diabetes Mellitus (MODY) 05/2007
1	Diabetes Mellitus 05/2007
1	Paresis (Hemiparesis) 05/2005
1	Body Weight (Weight, Body) 10/2001
1	Cardiomegaly (Heart Hypertrophy) 10/2001
1	Ventricular Remodeling 10/2001
1	Heart Failure 10/2001
1	Myocardial Infarction 06/2001
1	Cardiovascular Diseases (Cardiovascular Disease) 06/2001
1	Lung Neoplasms (Lung Cancer) 05/2001
1	Hemorrhage 12/2000
1	Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar) 07/2000
1	Atherosclerosis 02/2000

Drug/Important Bio-Agent (IBA)

7	MK-886IBA 01/2005 - 07/2000
2	EpitopesIBA 01/2014 - 07/2007
2	Carvedilol (Coreg)FDA LinkGeneric 07/2007 - 05/2007
2	Metoprolol (Toprol-XL)FDA LinkGeneric 07/2007 - 05/2007
2	Lipoxygenase InhibitorsIBA 01/2005 - 05/2001
2	Complementary DNA (cDNA)IBA 01/2002 - 07/2000
2	Abciximab (ReoPro)FDA Link 06/2001 - 12/2000
2	Platelet Membrane Glycoprotein IIbIBA 06/2001 - 12/2000
2	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 05/2001 - 07/2000
1	CateninsIBA 01/2014
1	IntegrinsIBA 01/2014
1	Interferon-gamma (Interferon, gamma)IBA 09/2011
1	Pyruvate Dehydrogenase Acetyl-Transferring KinaseIBA 11/2009
1	NitrogenIBA 11/2009
1	Metformin (Glucophage)FDA LinkGeneric 07/2007
1	ThiazolidinedionesIBA 07/2007
1	Insulin (Novolin)FDA Link 07/2007
1	Biological ProductsIBA 01/2007
1	Oxygen (Dioxygen)IBA 11/2006
1	Deoxyglucose (2 Deoxy D glucose)IBA 11/2006
1	serum P-component (CIt)IBA 05/2005
1	CaspasesIBA 01/2005
1	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2004
1	LigandsIBA 11/2003
1	Dactinomycin (Actinomycin)FDA LinkGeneric 11/2003
1	Proteins (Proteins, Gene)FDA Link 04/2002
1	Cisplatin (Platino)FDA LinkGeneric 01/2002
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2002
1	Growth Factor ReceptorsIBA 01/2002
1	Messenger RNA (mRNA)IBA 01/2002
1	Endothelins (Endothelin)IBA 10/2001
1	enrasentanIBA 10/2001
1	SaltsIBA 10/2001
1	Endothelin Receptor AntagonistsIBA 10/2001
1	Platelet Membrane GlycoproteinsIBA 06/2001
1	SC 41661AIBA 05/2001
1	Free RadicalsIBA 05/2001
1	Heparin (Liquaemin)FDA LinkGeneric 12/2000
1	Lipoproteins (Lipoprotein)IBA 02/2000

Therapy/Procedure

9	Therapeutics 02/2011 - 07/2000
2	Drug Therapy (Chemotherapy) 07/2007 - 01/2002
2	Percutaneous Coronary Intervention 06/2001 - 12/2000
1	Prostatectomy (Retropubic Prostatectomy) 06/2012
1	Immunotherapy 07/2007
1	Radiotherapy 07/2001
1	Drug Tapering 12/2000